|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-11-27
|
|
pubmed:abstractText |
Daily oral tablet bisphosphonate therapy for Paget's disease of bone may cause serious upper gastrointestinal adverse events. A once-weekly alendronate 280 mg oral buffered solution was compared with an alendronate 40 mg/day tablet. While both were similarly effective, the tablet appeared to be better tolerated in this study.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1433-2965
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
141-50
|
|
pubmed:meshHeading |
pubmed-meshheading:18536953-Administration, Oral,
pubmed-meshheading:18536953-Aged,
pubmed-meshheading:18536953-Alendronate,
pubmed-meshheading:18536953-Analysis of Variance,
pubmed-meshheading:18536953-Bone Density Conservation Agents,
pubmed-meshheading:18536953-Double-Blind Method,
pubmed-meshheading:18536953-Drug Administration Schedule,
pubmed-meshheading:18536953-Female,
pubmed-meshheading:18536953-Humans,
pubmed-meshheading:18536953-Male,
pubmed-meshheading:18536953-Middle Aged,
pubmed-meshheading:18536953-Osteitis Deformans,
pubmed-meshheading:18536953-Solutions,
pubmed-meshheading:18536953-Tablets
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease.
|
|
pubmed:affiliation |
University of Sydney, 56 St Johns Ave, Gordon, NSW, 2072, Australia. mjhooper@bigpond.net.au
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
In Vitro,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
